1. In Vivo
  2. >>Market Access

Podcast: Navigating Challenges – The Changing Role Of Big Pharma

Podcast Interview With AstraZeneca's Stefan Woxström

 
• By Lucie Ellis-Taitt

Stefan Woxström, senior vice president of AstraZeneca, Europe and Canada, discusses the growing challenges in the industry and addresses the role big pharma must adopt in resolving them.

In Vivo Podcast
• Source: Shutterstock

"I have to go beyond just focusing on bringing medicine to patients but also start looking at what health care systems really need."

In this latest instalment of the In Vivo podcast, Stefan Woxström, senior VP of AstraZeneca, Europe and Canada, draws attention to the role big pharma can adopt in delivering preventative and sustainable health care. Woxström analyzes the changing role of technology in disease prevention and looks forward to the future of AstraZeneca. 

Timestamps:

Introduction - 00:00

What concerns do you hold for the future of health care? - 4:50 

How does big pharma need to act to protect innovation? – 7:20 

Role within preventative health- 11:56

Devices in medicine- 16:17

Goals for the business in the next 12-18 months- 22:04

How will work adapt to achieve these aims? - 24:00

More from Market Access

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

US Health System Redesign Critical, NAM’s Medical Experts Warn Trump Government

 
• By Ashley Yeo

The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.

Future Of 340B Rebate Models Hinges On Regulatory Decision Point

 
• By Ed Silverman

As pharmaceutical companies seek to transform how drug discounts are delivered under the 340B program, a federal ruling reinforces HRSA's authority. The industry must now wait for critical guidance from the Trump administration that could reshape compliance strategies and financial outcomes.

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

 
• By David Wild

The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.